Daytrana methylphenidate patches recalled for defective delivery system
Noven Pharmaceuticals is recalling Daytrana methylphenidate transdermal patches for a defective delivery system that fails to meet shear specifications. The recall affects specific lots distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall for a prescription CNS stimulant with a defective delivery system. The hazard is a risk-of-harm product (a controlled substance where delivery system integrity directly affects patient safety), with no illnesses or injuries reported in the source material.
Plain-English summary
Noven Pharmaceuticals Inc is recalling specific lots of Daytrana (methylphenidate) 20mg transdermal patches due to a defective delivery system. The patches are out of specification for shear, meaning they do not meet the required structural standards for the transdermal delivery system.
The affected lots are: 91957 and 92197 (expiring 7/2023); 92476 (expiring 9/2023); and 92477 (expiring 10/2023). These patches were distributed nationwide.
Daytrana is a prescription medication used to treat attention-deficit/hyperactivity disorder. A defective delivery system could affect proper absorption and delivery of the medication. Patients using Daytrana should check if they have patches from the affected lots and contact their pharmacy or healthcare provider with questions.
The recalled product
- Product
- DAYTRANA (METHYLPHENIDATE)
- Brand
- DAYTRANA
- Manufacturer
- Noven Pharmaceuticals Inc
- Category
- Drug — Transdermal Patch
- Hazard
- delivery-system-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot#: 91957
- 92197
- Exp. 7/2023
- 92476
- Exp. 9/2023
- 92477
- Exp. 10/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DAYTRANA
- HighDaytrana Methylphenidate Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
- HighDaytrana Methylphenidate Patches Recalled for Defective Transdermal Delivery System
FDA (Drugs) · 2023-03-29
- ModerateDaytrana Methylphenidate Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
- HighDaytrana transdermal methylphenidate patches recalled for adhesive defect
FDA (Drugs) · 2022-12-07
- HighMethylphenidate Patch Recall: Defective Delivery System and Adhesive Issues
FDA (Drugs) · 2022-07-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27